Objective:To investigate the clinical characteristics and treatment outcomes of toxoplasmic retinochoroiditis (TRC).Methods:A retrospective clinical case study. From October 2022 to May 2026, 17 patients (21 eyes) diagnosed with TRC at Chengdu Aidi Eye Hospital were included in the study. Among them, there were 8 males and 9 females; 13 cases were unilateral and 4 cases were bilateral. The patients' age was (35.10±19.38) years old, and the disease duration ranged from 3 days to 6 months. Among the 21 eyes, 17 were active lesion eyes and 4 were old lesion eyes (all in the contralateral eyes of patients with bilateral involvement). All affected eyes underwent best corrected visual acuity (BCVA) testing, fundus color photography, optical coherence tomography examination, as well as serological and aqueous humor arthropod-specific antibody. Empirical anti-toxoplasma treatment was given before a definite diagnosis was made. After serological and laboratory tests confirmed the diagnosis, the original treatment plan was maintained. Among the 17 patients, 13 patients received oral sulfamethoxazole and azithromycin, and 4 patients received oral azithromycin. The follow-up period after treatment was 1.5 to 6.0 months. The clinical manifestations and treatment outcomes of the patients were retrospectively analyzed.Results:Vitreous opacity and inflammatory cells were observed in all 17 eyes. Retinal lesions were predominantly located in the posterior pole, mainly around the macula. Among the 17 eyes with active lesions, most showed irregularly shaped, ill-defined, grayish-white infiltrative lesions; the inner and outer retinal neuroepithelial layers were involved in 14 and 3 eyes, respectively. The 4 eyes with old lesions showed retinal atrophy, scarring, and changes in the retinal pigment epithelium (RPE) layer. At initial presentation, BCVA ranged from counting fingers to 1.0; 3 eyes had counting-finger vision, all associated with foveal involvement. After treatment, the inflammatory response in active lesions subsides, edema resolves, and the lesions gradually become quiescent and scarred; involvement of the inner neuroepithelial layer led to structural thinning, scarring, and formation of preretinal proliferative membranes, whereas those with outer layer involvement showed RPE and superficial choroidal scar formation. BCVA improved significantly in 14 eyes, whereas visual recovery was poor in the 3 eyes with foveal involvement. The BCVA significantly improved in 14 eyes, but the vision recovery was poor in 3 eyes that affected the macular fovea. In this group, 1 eye was misdiagnosed as lymphoma and the treatment was delayed, eventually resulting in eyeball atrophy.Conclusions:TRC is mainly characterized by vitreous opacity and posterior pole retinal infiltration; after treatment, the inflammation can subside, but the involvement of the macular fovea is the main reason for poor visual prognosis. Delayed diagnosis and treatment can lead to eyeball atrophy. Early diagnosis and timely effective treatment are crucial for improving prognosis.